Page | |
EDITORIALS |
1002 | The severe asthma–obesity conundrum: Consequences for exertional dyspnoea and exercise tolerance in men and women
|
1006 | Would chronic mucus hypersecretion affect the clinical response to medications of COPD patients?
|
1008 | Quantitative computed tomography of the chest for fibrotic lung diseases: Prime time for its use in routine clinical practice?
|
1012 | Sealing the gap in bronchoscopic lung volume reduction
|
COMMENTARIES |
1015 | Innovative cystic fibrosis drug development: A perspective
|
1018 | What have we learnt from real-life research in asthma and COPD? Standards and novel designs for the future
|
1022 | Are we coming out from the COVID-19 pandemic?
Chi Chiu Leung MBBS, FCCP, FFPH, Andrew C K Lee MB ChB, MSc, MD, FRSPH, MFPH, MRCGP
10.1111/resp.14403 |
ORIGINAL ARTICLES |
Asthma and Allergy |
1025 | Factors associated with 6-min walk distance in severe asthma: A cross-sectional study
Anders Pitzner-Fabricius, Vanessa L Clark, Vibeke Backer, Peter G Gibson, Vanessa M McDonald
10.1111/resp.14323
Among adults with severe asthma in Australia, association between 6-min walk distance (6MWD) and clinical and biological factors was examined. Asthma control and BMI were significantly associated with 6MWD.
See related Editorial |
COPD |
1034 |
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trial
Philip J Thompson, Gerard J Criner, Mark T Dransfield, David M G Halpin, MeiLan K Han, David A Lipson, Ghassan J Maghzal, Fernando J Martinez, Dawn Midwinter, Dave Singh, Lee Tombs, Robert A Wise
10.1111/resp.14339
The relationship between chronic mucus hypersecretion (CMH) and treatment response to FF/UMEC/VI, FF/VI or UMEC/VI was assessed in symptomatic patients with COPD and a history of exacerbations. FF/UMEC/VI reduced exacerbation rates versus FF/VI and UMEC/VI irrespective of CMH status; similar improvements in health status and lung function were observed.
See related Editorial |
Interstitial Lung Disease |
1045 | Quantitative computed tomography predicts outcomes in idiopathic pulmonary fibrosis
Stephen M Humphries, John A Mackintosh, Helen E Jo, Simon L F Walsh, Mario Silva, Lucio Calandriello, Sally Chapman, Samantha Ellis, Ian Glaspole, Nicole Goh, Christopher Grainge, Peter M A Hopkins, Gregory J Keir, Yuben Moodley, Paul N Reynolds, E Haydn Walters, David Baraghoshi, Athol U Wells, David A Lynch, Tamera J Corte
10.1111/resp.14333
The extent of pulmonary fibrosis, measured objectively at baseline computed tomography using a deep learning algorithm, is associated with disease progression and mortality, independent of pulmonary function.
See related Editorial |
1054 | Antifibrotics and lung transplantation: A Spanish multicentre case-controlled study
Víctor Manuel Mora Cuesta, David Iturbe Fernández, Silvia Aguado Ibáñez, Gabriel Anguera de Francisco, Juan Margallo Iribarnegaray, Javier Carrillo Hernández-Rubio, Juan Pablo Reig Mezquida, Virginia Pérez Luz, Rosalía Laporta Hernández, Alicia de Pablo Gafas, Amparo Solé Jover, José Manuel Cifrián Martínez
10.1111/resp.14352
Our findings on the safety of antifibrotic treatment in IPF patients undergoing lung transplantation show that patients receiving antifibrotic treatment at the time of transplantation have similar post-surgery outcomes to those receiving a lung transplant without antifibrotic treatment, although the adverse effect of chest wall dehiscences in transplant recipients with antifibrotic treatment appeared earlier. |
Interventional Pulmonology |
1064 | Reversal of collateral ventilation using endoscopic polymer foam in COPD patients undergoing endoscopic lung volume reduction with endobronchial valves: A controlled parallel group trial
Alvin J Ing, Anand Jayapadman, Woo-Veen Kim, Chelsea Ly, Kevin Ho-Shon, Paul Lilburn, Alan Carew, Benjamin J H Ng, Tajalli Saghaie, Jonathan P Williamson
10.1111/resp.14338
In chronic obstructive pulmonary disease (COPD) patients otherwise suitable for endoscopic lung volume reduction (ELVR) with endobronchial valves (EBVs) to the left upper lobe, but previously excluded due to collateral ventilation (CV), this can be successfully reversed with endoscopic polymer foam (EPF) prior to EBV insertion. Clinical improvements are similar to a group undergoing ELVR with no CV.
See related Editorial |
Lung Function |
1073 | Breath-holding physiology, radiological severity and adverse outcomes in COVID-19 patients: A prospective validation study
Ludovico Messineo, Francesco Fanfulla, Leonardo Pedroni, Floriana Pini, Andrea Borghesi, Salvatore Golemi, Guido Vailati, Kayla Kerlin, Atul Malhotra, Luciano Corda, Scott Sands
10.1111/resp.14336
An elevated breath-holding-based prediction score was associated with increased COVID-19 incident adverse outcome risk in a validation cohort of 110 hospitalized COVID-19 patients. The prediction score was also positively associated with increasing radiological severity, per chest x-ray and computed tomography (CT) assessment. Our prediction score performed better than the previously-validated, biomarker-based 4C-score. |
FORUM AND DEBATE |
Scientific Letter |
1083 | Sleep and circadian health 6 months after critical COVID-19 disease
Adriano D S Targa, Iván D Benítez, Jessica González, Gerard Torres, Sally Santisteve, Rafaela Vaca, Olga Minguez, Maria Aguilà, Paola Carmona, Anna Moncusí-Moix, Clara Gort-Paniello, Gonzalo Labarca, Jesús Caballero, Carme Barberà, Antoni Torres, David de Gonzalo-Calvo, Ferran Barbé
10.1111/resp.14390 |
LETTERS FROM ASIA-PACIFIC AND BEYOND |
1089 |
Leading women in Respiratory Medicine: Letter from the ERS
Meropi Karakioulaki BSc, MSc, MD, Anita Simonds MD, FRCP, FERS, Daiana Stolz MD, MPH, FERS, FCCP
10.1111/resp.14384
Special Series: Leading Women in Respiratory Medicine
Series Editors: Natasha Smallwood and Fanny Wai San Ko
See related editorial |
1091 | Letter from Sri Lanka
|
1093 | Letter from Slovakia
|
CORRIGENDUM |
1095 | Treatable traits in the NOVELTY study
|